Cassava, Alzheimer
Alzheimer’s Drug Developer Cassava Paying $40 Million to Settle Doctored Data Claims
The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug results look more promising.
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial
Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic treatment of Alzheimer's disease,
US charges Cassava Sciences, two former executives for misleading claims about Alzheimer’s clinical trial
The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former executives for misleading claims about the results of Alzheimer’s clinical trials.
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the Alzheimer's drug simufilam, and agreed to pay fines.
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for misleading claims about the results of Alzheimer's clinical trials.
Afro7h
Neurologist speaks on fighting Alzheimer’s Disease with diet and exercise
Discover how exercise, a healthy diet, and socialization can help combat Alzheimer's disease. Learn more about the importance ...
Barbara Corcoran secretly cared for her mother with Alzheimer's for years. She was waiting for her own dementia risk before speaking out.
The Shark Tank investor kept her mom's diagnosis a secret until she could evaluate her own risk of Alzheimer's. She's finally ...
Two upcoming weekend walks to raise money for Alzheimer’s, Huntington’s disease
Hundreds of walkers will lace up their shoes this weekend to raise money to battle Alzheimer’s and Huntington’s Disease.
Alzheimer’s disease could be slowed by boosting a certain protein in the brain, researchers say
Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...
Dietary compound increases longevity and protects against Alzheimer's disease in experimental models
Researchers from the Color and Food Quality group at the Faculty of Pharmacy (University of Seville), in collaboration with ...
Sacramento woman walks for a cure to Alzheimer's: "It's the worst disease"
With nearly seven million people currently living with Alzheimer's in the US, advocates stress the urgency of finding a cure, ...
Psychology Today2d
What Does Obesity Have to Do With Alzheimer’s Disease?
Leptin, a hormone that helps with weight control, also plays a role in normal cognition. Leptin resistance occurs when the ...
Light pollution in cities and towns has been linked to Alzheimer’s disease
New research says that light pollution and Alzheimer's may actually have a connection. Here's what you need to know.
Astrocytes study identifies a new therapeutic target for Alzheimer's disease
Worldwide, at least 50 million people are believed to be living with a form of dementia. Alzheimer's disease is the most ...
Gizmodo Science Fair: Treating Alzheimer’s Disease With Ultrasound
Scientists at the West Virginia University Rockefeller Neuroscience Institute hope to unlock the true potential of drugs ...
Woodland Daily Democrat on MSN12h
Assemblywoman announces bill in support of Californians living with Alzheimer’s disease
This bill will update the Alzheimer’s Disease and Related Conditions (ADRD) Advisory Committee code to remove stigmatizing and outdated language by broadening caregiver terminology and removing ...
McKnight's Long-Term Care News6h
Journalists question safety and effectiveness of new Alzheimer’s drug
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...